According to a recent article by Marijuana Moment, the Food and Drug Administration is seeking to award a contract “to help study CBD as the agency develops regulations for products containing the non-intoxicating cannabinoid.”
The Food and Drug Administration (FDA) appears to have published the contractor information on its website on August 13, 2020. According to the post:
“The Food Drug Administration is seeking a Contractor who shall provide support to the FDA by collecting samples and assessing the quantities of CBD and related cannabinoids, as well as potential associated contaminants such as toxic elements, pesticides, industrial chemicals, processing solvents, and microbial contaminants, in foods and cosmetics through surveys of these commodities. The purpose of these studies will be to develop a better understanding of the quantities of CBD and associated cannabinoids and their distribution.”
The position is also in line with the agency’s ongoing efforts to understand the CBD marketplace. In July 2020, the FDA submitted a report to Congress concerning the CBD. The report, titled Sampling Study of the Current Cannabidiol Marketplace to Determine the Extent That Products are Mislabeled or Adulterated, includes research conducted by the agency on the quality and contents of CBD products. The report, which can be found here, reads in part:
“FDA believes that understanding the characteristics of marketed CBD products is critical to making informed decisions about how best to protect public health in the current marketplace.”
All information is for general informational and educational purposes only. Nothing should be interpreted as legal or wellness advice.